APPLIED GENETIC TECHNOLOGIES CORPORATION (NASDAQ:AGTC) Files An 8-K Other Events
Item 8.01. Other Events.
On June 24, 2021, Applied Genetic Technologies Corporation issued a press release reporting 12-month data from its ongoing phase 1/2 Achromatopsia (ACHM) clinical trials. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|99.1 || ||Press release dated June 24, 2021. |
APPLIED GENETIC TECHNOLOGIES CORP Exhibit
EX-99.1 2 d175382dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene – Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing- – Dosing of pediatric patients in ACHM B3 program and ACHM A3 program is expected to be completed in August 2021 – -Conference call to review data today at 8:00am ET- GAINESVILLE,…
To view the full exhibit click
About APPLIED GENETIC TECHNOLOGIES CORPORATION (NASDAQ:AGTC)
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
An ad to help with our costs